Cargando…
A pilot study of rizatriptan and visually-induced motion sickness in migraineurs
Background: Limited evidence suggests that rizatriptan given before vestibular stimulation reduces motion sickness in persons with migraine-related dizziness. The present study was designed to test whether rizatriptan is also effective in protecting against visually-induced motion sickness and to te...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726576/ https://www.ncbi.nlm.nih.gov/pubmed/19680473 |
_version_ | 1782170627715629056 |
---|---|
author | Furman, Joseph M. Marcus, Dawn A. |
author_facet | Furman, Joseph M. Marcus, Dawn A. |
author_sort | Furman, Joseph M. |
collection | PubMed |
description | Background: Limited evidence suggests that rizatriptan given before vestibular stimulation reduces motion sickness in persons with migraine-related dizziness. The present study was designed to test whether rizatriptan is also effective in protecting against visually-induced motion sickness and to test whether rizatriptan blocks the augmentation of motion sickness by head pain. Material and Methods: Using randomized double-blind, placebo-controlled methodology, 10 females, 6 with migrainous vertigo (V+) and four without vertigo (V-) received 10 mg rizatriptan or placebo two hours prior to being stimulated by optokinetic stripes. Visual stimulation was coupled with three pain conditions: no pain (N), thermally-induced hand pain (H) and temple pain (T). Motion sickness and subjective discomfort were measured. Results: Motion sickness was less after pre-treatment with rizatriptan for 4 of 10 subjects and more for 5 of 10 subjects. Augmentation of motion sickness by head pain was seen in 6 of 10 subjects; this effect was blunted by rizatriptan in 4 of these 6 subjects. Subjective discomfort was significantly more noticeable in V+ subjects as compared with V- subjects. Conclusions: These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain. |
format | Text |
id | pubmed-2726576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-27265762009-08-13 A pilot study of rizatriptan and visually-induced motion sickness in migraineurs Furman, Joseph M. Marcus, Dawn A. Int J Med Sci Research Paper Background: Limited evidence suggests that rizatriptan given before vestibular stimulation reduces motion sickness in persons with migraine-related dizziness. The present study was designed to test whether rizatriptan is also effective in protecting against visually-induced motion sickness and to test whether rizatriptan blocks the augmentation of motion sickness by head pain. Material and Methods: Using randomized double-blind, placebo-controlled methodology, 10 females, 6 with migrainous vertigo (V+) and four without vertigo (V-) received 10 mg rizatriptan or placebo two hours prior to being stimulated by optokinetic stripes. Visual stimulation was coupled with three pain conditions: no pain (N), thermally-induced hand pain (H) and temple pain (T). Motion sickness and subjective discomfort were measured. Results: Motion sickness was less after pre-treatment with rizatriptan for 4 of 10 subjects and more for 5 of 10 subjects. Augmentation of motion sickness by head pain was seen in 6 of 10 subjects; this effect was blunted by rizatriptan in 4 of these 6 subjects. Subjective discomfort was significantly more noticeable in V+ subjects as compared with V- subjects. Conclusions: These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain. Ivyspring International Publisher 2009-08-06 /pmc/articles/PMC2726576/ /pubmed/19680473 Text en © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. |
spellingShingle | Research Paper Furman, Joseph M. Marcus, Dawn A. A pilot study of rizatriptan and visually-induced motion sickness in migraineurs |
title | A pilot study of rizatriptan and visually-induced motion sickness in migraineurs |
title_full | A pilot study of rizatriptan and visually-induced motion sickness in migraineurs |
title_fullStr | A pilot study of rizatriptan and visually-induced motion sickness in migraineurs |
title_full_unstemmed | A pilot study of rizatriptan and visually-induced motion sickness in migraineurs |
title_short | A pilot study of rizatriptan and visually-induced motion sickness in migraineurs |
title_sort | pilot study of rizatriptan and visually-induced motion sickness in migraineurs |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726576/ https://www.ncbi.nlm.nih.gov/pubmed/19680473 |
work_keys_str_mv | AT furmanjosephm apilotstudyofrizatriptanandvisuallyinducedmotionsicknessinmigraineurs AT marcusdawna apilotstudyofrizatriptanandvisuallyinducedmotionsicknessinmigraineurs AT furmanjosephm pilotstudyofrizatriptanandvisuallyinducedmotionsicknessinmigraineurs AT marcusdawna pilotstudyofrizatriptanandvisuallyinducedmotionsicknessinmigraineurs |